Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO)’s share price reached a new 52-week low during trading on Thursday . The company traded as low as C$0.39 and last traded at C$0.36, with a volume of 34846 shares. The stock had previously closed at C$0.38.
Aptose Biosciences Trading Down 9.3 %
The company has a debt-to-equity ratio of 670.80, a current ratio of 0.80 and a quick ratio of 5.41. The company has a market cap of C$6.16 million, a price-to-earnings ratio of -0.07 and a beta of 1.36. The business has a 50 day simple moving average of C$0.52 and a 200 day simple moving average of C$0.85.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- What is the Australian Securities Exchange (ASX)
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
